Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 20,000,000
Countries
Sector(s)
Ireland : € 10,000,000
Germany : € 10,000,000
Industry : € 20,000,000
Signature date(s)
1/12/2016 : € 5,000,000
1/12/2016 : € 5,000,000
1/12/2016 : € 5,000,000
1/12/2016 : € 5,000,000
Link to source

Summary sheet

Release date
15 December 2016
Status
Reference
Signed | 01/12/2016
20160461
Project name
Promoter - financial intermediary
AMRYT PHARMA (EGFF)
AMRYT PHARMACEUTICALS DAC
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 20 million
EUR 46 million
Location
Sector(s)
Description
Objectives

This project will finance the research and development (R&D) investment and growth of Amryt Group. Amryt Group is an orphan disease speciality pharmaceutical company which may be characterised by medium to high growth and very high research and development (R&D) intensity. The company is focusing on bringing innovative orphan drugs to the market, addressing clearly identified high unmet medical needs, and helping increase the quality of life of patients suffering from rare diseases. The R&D intensity of the company is reflected in the active drug development activity and also the fact that it already owns four patent families covering Europe, the US and other major markets (e.g. Japan, Australia, China).

The scope of the company's research, development and innovation (RDI) investments is in line with the priority areas of Horizon 2020 (Health, Demographic Change and Wellbeing). Furthermore, it addresses a constant demand for novel treatments also for people suffering from rare diseases. In addition, positive externalities would derive from the development of novel drugs contributing to the increase in quality of life mainly through pain reduction.

Environmental aspects
Procurement

The promoter's investments concern research, development and innovation activities as well as production deployment that will be in large part carried out in existing facilities already authorised for similar activities and volumes and that do not require an environmental impact assessment (EIA) according to the relevant EU directives.

The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by the EU directives on procurement.

Link to source
Summary sheet

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

scoreboard - EUROPEAN GROWTH FINANCE FACILITY
Publication Date
13 Sep 2019
Document Language
English
Main Topic
lending
Document Number
122912044
Document Focus
EFSI legal requirements
Document Type
Scoreboard
Project Number
20180667
Last update
19 Aug 2020
Sector(s)
Services
Countries
Bulgaria, Kenya, Ghana, Mexico, Philippines
Publicly available
Download now
Link to source

News & Stories

Other links

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications